Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial

Y. Cheng, R. Yang, J. Chen, W. Zhang, C. Xie, Q. Hu,N. Zhou, C. Huang, S. Wei,H. Sun, X. Li, Y. Yu, J. Lai,H. Yang, H. Fang, H. Chen, P. Zhang,K. Gu, Q. Wang, J. Shi,T. Yi, X. Xu, X. Ye,D. Wang, C. Xie, C. Liu, Y. Zheng, D. Lin, W. Zhuang, P. Lu, G. Yu, J. Li, Y. Gu, B. Li, R. Wu, O. Jiang, Z. Wang, G. Wu, H. Lin, D. Zhong, Y. Xu, Y. Shu, D. Wu, X. Chen, J. Wang, M. Wang

Journal of thoracic oncology（2023）

引用 0|浏览10

暂无评分

摘要

Small-cell lung cancer (SCLC) is a recalcitrant malignancy. Despite immunochemotherapy showed promise with a 2-month overall survival (OS) benefits in extensive-stage SCLC (ES-SCLC), improving long-term survival remains an unmet need. Limited benefit might attribute to the complicated SCLC microenvironment, which is characterized by immunosuppression, angiogenesis and vascularization. Tumor microenvironment reprogramming and tumor vessel normalization could promote immune cell infiltration, obtaining synergistic effects with immunotherapy.

查看译文

关键词

PD-L1 inhibitor,Anlotinib,ES-SCLC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要